| Dr Hans Joseph Meissnest, PT, DPT | |
|
1496 W Hoosier Blvd Rm 220, Peru, IN 46970-3727 | |
| (765) 472-5025 | |
| (765) 472-8999 |
| Full Name | Dr Hans Joseph Meissnest |
|---|---|
| Gender | Male |
| Speciality | Physical Medicine & Rehabilitation - Sports Medicine |
| Location | 1496 W Hoosier Blvd Rm 220, Peru, Indiana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1730258732 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2081S0010X | Physical Medicine & Rehabilitation - Sports Medicine | 05005051A (Indiana) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Hans Joseph Meissnest, PT, DPT 1942 Marjorie Ln, Kokomo, IN 46902-3848 Ph: (505) 366-9559 | Dr Hans Joseph Meissnest, PT, DPT 1496 W Hoosier Blvd Rm 220, Peru, IN 46970-3727 Ph: (765) 472-5025 |
News Archive
A pioneering University of Liverpool research team have published a study that identifies the mechanism in the human body that causes resistance of pancreatic cancer cells to chemotherapy.
The American Gastroenterological Association Research Foundation is pleased to announce the 2014 AGA Research Scholars. The AGA Research Scholar Awards program, launched in 1984, enables young investigators to develop independent and productive research careers in digestive diseases. This year, the AGA Research Scholar Awards fund an additional year allowing for three consecutive years of funding.
In women, hormone therapy is a risk factor for venous thrombosis, a blood clot forming deep inside the vein.
Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced that its corporate partner, Boston Scientific Corporation (NYSE: BSX), has released comprehensive data from the TAXUS ATLAS clinical program, a series of global, prospective, single-arm trials evaluating the TAXUS(R) Liberté(R) Paclitaxel-Eluting Stent System in a variety of lesions and patient groups. Three-year results from the TAXUS ATLAS Small Vessel and Long Lesion Trials continue to show significant advantages for the newer TAXUS Liberté Stent when compared to the first-generation TAXUS(R) Express(R) Stent.
Lantis Laser Inc., announced today that it has signed a Letter of Intent to merge with Perio-Imaging Inc., a private New York based company. The merger would be an all stock transaction and closing, among other conditions, would be subject to raising the required funding to complete the proposed merged company's product development program. The name of the new merged company will be announced upon closing.
› Verified 5 days ago